Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuvigil Gets Protection Until 2023 Under New Patent

This article was originally published in The Pink Sheet Daily

Executive Summary

Composition-of-matter claim for “enantiomers of modafinil” adds a decade to the patent life of Cephalon’s follow-on wakefulness treatment.

You may also be interested in...



FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash

Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.

FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash

Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.

Provigil Will Remain Cephalon’s Marketing Focus As Partner Takeda Adds Reps

Nuvigil will be a “modest” launch in 2007 as Cephalon looks to expand labeling ahead of enhanced marketing in 2010.

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel